This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Allakos Inc. (ALLK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
by Zacks Equity Research
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.
Allakos Inc. (ALLK) Stock Moves -1.6%: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed the most recent trading day at $4.31, moving -1.6% from the previous trading session.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Allakos Inc. (ALLK) closed at $4.80, marking a -1.64% move from the previous day.
Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed the most recent trading day at $5.69, moving -0.52% from the previous trading session.
Allakos Inc. (ALLK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed at $5.97 in the latest trading session, marking a +1.7% move from the prior day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed at $5.08 in the latest trading session, marking a -0.39% move from the prior day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed the most recent trading day at $5.58, moving -0.18% from the previous trading session.
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.
Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround
by Zacks Equity Research
Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.
Implied Volatility Surging for Allakos (ALLK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Implied Volatility Surging for Allakos (ALLK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Moving Average Crossover Alert: Allakos (ALLK)
by Zacks Equity Research
Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.